Literature DB >> 573232

Metabolic effects of combined sulphonylurea and metformin therapy in maturity-onset diabetice.

M Nattrass, L Hinks, P Smythe, P G Todd, K G Alberti.   

Abstract

Twelve hour metabolic studies have been performed in two groups of maturity-onset diabetics treated either by sulphonylurea and metformin therapy or sulphonylurea therapy alone. There was no significant difference in blood glucose concentration between the two groups although serum insulin concentration was significantly higher in the group treated by sulphonylurea therapy alone. Concentrations of several intermediary metabolites were higher when metformin formed part of the therapy. Thus, mean blood lactate, pyruvate, alanine and total ketone body concentrations and the lactate/pyruvate ratio and 3-hydroxybutyrate/acetoacetate ratio were all significantly elevated during sulphonylurea and metformin therapy. It is concluded that the use of metformin with a sulphonylurea results in widespread abnormalities in blood concentrations of intermediary metabolites.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 573232     DOI: 10.1055/s-0028-1092733

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  5 in total

1.  Potential non-hypoxic/ischemic causes of increased cerebral interstitial fluid lactate/pyruvate ratio: a review of available literature.

Authors:  Daniel B Larach; W Andrew Kofke; Peter Le Roux
Journal:  Neurocrit Care       Date:  2011-12       Impact factor: 3.210

2.  Low dose metformin in the treatment of type II non-insulin-dependent diabetes: clinical and metabolic evaluations.

Authors:  F Gregorio; F Ambrosi; P Marchetti; S Cristallini; R Navalesi; P Brunetti; P Filipponi
Journal:  Acta Diabetol Lat       Date:  1990 Apr-Jun

Review 3.  Oral antidiabetic drug use in the elderly.

Authors:  R Bressler; D G Johnson
Journal:  Drugs Aging       Date:  1996-12       Impact factor: 3.923

4.  The effect of diet on intermediary metabolite concentrations in Type 2 (non-insulin-dependent) diabetes mellitus.

Authors:  M C Sheppard; J Burrin; K G Alberti; M Nattrass
Journal:  Diabetologia       Date:  1983-05       Impact factor: 10.122

5.  The status of metformin in Canada.

Authors:  O J Lucis
Journal:  Can Med Assoc J       Date:  1983-01-01       Impact factor: 8.262

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.